Reports Q1 revenue $2.3M, consensus $198K. The increase in revenue was primarily attributable to license fees from partners in Q1 of 2025, including $1.5M in milestones from Arctic Vision and $0.8M in other revenue for training, services and the sales of SCS Microinjector kits to licensees. As of March 31, Clearside’s cash and cash equivalents totaled $13.6M. The company believes it will have sufficient resources to fund its planned operations into Q4 of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical announces six presentations related to CLS-AX
- Buy Rating for Clearside Biomedical Backed by Promising Trial Results and FDA Alignment
- Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges
- Clearside Biomedical price target lowered to $4 from $6 at Needham
- Buy Rating for Clearside Biomedical: Strategic Partnerships and Financial Stability Drive Positive Outlook
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue